FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound of formulawherein Rrepresents hydrogen or Calkyl; Rrepresents groupsandor may be specified in a group consisting of, wherein Rrepresents hydrogen, halogen or aryl optionally substituted by halogen; X represents a bond, -(CH)-, -CHRCH-, -CHR(CH)-, -O-CHRCH- or -(Ccyclopropyl)-CH-CH-, and R represents Calkyl or Calkyl substituted by halogen; Rrepresents a) Calkyl; b) hydrogen; c) NH-phenyl optionally substituted by one or more substitutes specified in halogen or Calkyl substituted by halogen; d) NH-6-merous heteroaryl containing 1 or 2 heteroatoms N optionally substituted by one or more substitutes specified in halogen or C-alkyl substituted by halogen; e) (CR'R')-C-cycloalkyl optionally substituted by halogen, Calkyl, Calkyl substituted by halogen, halogen-substituted phenyl or heteroaryl, which represents pyridine; f) 6-merous heterocycloalkyl containing 1 or 2 heteroatoms specified in N and O, optionally substituted by halogen or Calkyl substituted by halogen; g) (CR'R')-5-6-merous monocyclic or 9-10-mrous bicyclic heteroaryl containing 1-3 heteroatoms specified in N, S and O, optionally substituted by halogen, Calkoxy, Calkyl, substituted by halogen, Calkoxy substituted by halogen, Calkyl, Ccycloalkyl, NHC(O)-Calkyl, cyano, S(O)-Calkyl, NRRor 5-6-merous heteroaryl containing 1 or 2 heteroatoms, N or 6-merous heterocyclyl containing 1 or 2 heteroatoms specified in N, O and S, wherein S is optionally specified by two oxygen molecules, which is optionally substituted by halogen; h) (CR'R')-phenyl optionally substituted by halogen, Calkyl substituted by halogen, C-alkoxy substituted by halogen, Calkyl, Calkinyl, Calkoxy, CH-Calkoxy or cyano; i) -O(CH)-phenyl optionally substituted by halogen, Calkoxy or Calkyl substituted by halogen; R' and R' independently represent hydrogen, Calkoxy or Calkyl; or together with atom C may form C-cycloalkyl group; Rrepresents phenyl or 10-merous heteroaryl containing 1 heteroatom N, wherein the above aromatic rings are optionally substituted by one or more substitutes specified in halogen or Calkoxy; Rrepresents Calkyl, phenyl or 6-merous heteroaryl containing 1 heteroatom N, wherein the above aromatic rings are optionally substituted by one or more substituted specified in halogen, cyano or Calkoxy; Rrepresents hydrogen, Calkyl or phenyl substituted by halogen; R/Rindependently represent hydrogen, Calkyl or (CH)-O-Calkyl; m equals to 0, 1 or 2; n equals to 1, 2 or 3; o equals to 0 or 1; p equals to 0, 1 or 2; or their pharmaceutically acceptable acid addition salt. The invention also refers to compounds which represent 4-[2-((S)-2-amino-4,5-dihydrooxazol-4-yl)-ethyl]-N-(4-chlor-phenyl)-benzamide or (S)-4-(2-(2-amino-4,5-dihydrooxazol-4-yl)-ethyl)-N-(5-ethynylpyridin-2-yl)benzamide. The compositions according to the invention are applicable to produce a pharmaceutical composition having a high affinity to trace amine associated receptors.EFFECT: oxazoline derivatives applicable in treating depression, bipolar disorder, attention deficit/hyperactivity syndrome (ADHD), psychotic disorders, schizophrenia, Parkinson's disease, migraine and addictive substance abuse.23 cl, 1 tbl, 233 ex
OXAZOLINE DERIVATIVES FOR TREATING CNS DISORDERS